The Melanoma Nursing Initiative – Home › Forums › Immunotherapy › Reimbursement › Nivolumab dosing and Medicare › Reply To: Nivolumab dosing and Medicare
March 18, 2018 at 6:01 pm
#4746
Anonymous
Krista,
I spoke with our BMS rep about the potential higher incidence of infusion reactions at the 480 mg dose and was told it was not felt to be an issue. It will be interesting to see what the formal data shows as well.